Nuvisan

✨ Day 1 at #CPHI2024! ✨ What an incredible start to this global event! 🚀 It’s inspiring to be surrounded by industry leaders, innovators, and passionate professionals, all focused on shaping the future of #Pharma and #Healthcare. If you're attending, don't hesitate to connect – we Julian Bonss, Jean-Guy Boiteau, Isabel Dr. Zwick, Marjory GRAFFIN, Delphine MAUX, and Guillaume B. would love to discuss how we can support your project, and drive innovation together. Swing by our booth #5D139 and take a moment to join our NUVISAN guessing game for a chance to win a surprise box! The more times you join, the better your chances! https://lnkd.in/ehZATchJ #ScienceCRO #CPHI2024 #CPHIMilan #NUVISAN 

New Publication Alert 🎉 Our NUVISAN scientists Gareth Winckle and Ekkehard May have co-authored an opinion article alongside dermatology partners: Opportunities of Topical Drug Products in a Changing Dermatological Landscape, published in the European Journal of Pharmaceutical Sciences. The article explores the challenges of dermatology product development in today’s market, addressing both technical and commercial dynamics. It also highlights key considerations for the successful development of topical drug products. 👉 Read the full article here: https://lnkd.in/dxYkV6Tc ❤️ We’d love to hear your thoughts! Contact our experts Gareth Winckle and Ekkehard May for your specific need in topical product discovery & development projects. #Dermatology #Formulation #TopicalDrug #ScienceCRO #NUVISAN

Attending ELRIG Drug Discovery 2024 in London? Don’t miss the opportunity to check out our scientist’s poster and join our spotlight talks, happening today and tomorrow! 📰 Poster #145: Methods for Characterization and Derisking of Small Molecule Hits and Leads: Learnings from RAS-SOS1 and Hippo Pathway Screens, presented by Benjamin Bader 👨🏫 Spotlight Talk – October 2: Chemistry in Drug Discovery: Innovation, Collaboration, and Inspiration—Integrated Drug Discovery for PROTACs & Molecular Glues, presented by Yansong Wang 👨🏫 Spotlight Talk – October 3: An Immunologic Evaluation of T Cell Dynamics and Immune Subsets in Aged Mice, presented by Krzysztof Brzezinka Prefer a casual chat? Stop by the NUVISAN booth—our scientists would love to connect with you! #DrugDiscovery #PROTACs #Ageing #ScienceCRO #NUVISAN

👀 Looking for a scientific CMC partner? NUVISAN provides comprehensive bioanalytical and CMC services across the entire product life cycle, from early research and development to manufacturing and commercialization. With three GMP- and GLP-certified laboratories and over 100 analytical experts throughout Europe, we offer tailored solutions for your needs. In addition to traditional pharmaceutical testing—encompassing chemical, physico-chemical, and mechanical testing of raw materials, APIs, and finished drugs (small and large molecules, biologics), as well as batch release overseen by a Qualified Person (QP)—we assist our customers with analytical method development, method validation, ICH stability studies (including controlled storage), and photostability studies. 📯 Visit us at CPHI Milan, October 8-10! Our experts would be delighted to discuss your specific requirements and share the latest NUVISAN solutions with you. 📅 Booking an appointment with us-> https://lnkd.in/eV76T_Wq 🔎 Tale a look at our offer-> https://lnkd.in/eeic_5Ty #CDMO #ChemicalDevelopment #PharmaceuticalAnalysis #QualityPerson #CPHIMilan #NUVISAN #ScienceCRO #Formulation #ClinicalTrialSupply

🔬 Are you captivated by the journey from molecule to medicine, or are you the expert who makes it happen? Whichever the case, we’re sure you’ll enjoy the insights our scientists will share at the upcoming NUVISAN Meet & Learn event at the BioInnovation Institute in Copenhagen on October 29, 2024. Duy Nguyen will present NUVISAN’s integrated degrader capabilities. Benjamin Bader will guide you through KRAS inhibition, exploring SOS1, Fragment Screening, and HTS. Peter Staller will discuss a case study on the Hippo pathway in cancer, focusing on phenotypic screening, target identification, and lead optimization of novel small molecule inhibitors. 🍹 🤝 After the presentations, there will be plenty of networking opportunities with industry peers. Seats are limited! Reserve yours today → https://lnkd.in/eSzubjZh #MeetandLearn #ScienceCRO #NUVISAN #DrugDiscovery #Screening #Protacs #Oncology

📢 Visit Our Poster at ELRIG UK Drug Discovery 2024! Successful drug discovery demands cutting-edge technology platforms and comprehensive expertise across every stage of the value chain. At the upcoming ELRIG UK Drug Discovery conference in London, October 8-10, our scientist Benjamin Bader will present a poster showcasing methods for characterizing and de-risking small molecule hits and leads, with insights from RAS-SOS1 and Hippo pathway screening. We’d love to share key learnings from our biochemical and cell-based HTS projects with you! 💬 Interested in a deeper conversation with our experts? Stop by booth E07. Our scientists Benjamin Bader Krzysztof Brzezinka Yansong Wang look forward to connecting with you! 📅 Schedule a meeting with us-> https://lnkd.in/evq9JpNu #ELRIG #Biochemical #CellBasedHTS #HighthroughputScreening #ScienceCRO #NUVISAN

🎉 Join the Fun at CPHI with NUVISAN! At NUVISAN, we take science seriously—every decision we make is grounded in solid scientific evidence and close collaboration with our clients. Precision and accuracy are at the heart of everything we do. Do you have the spirit of a scientist? Test your skills with our CPHI guessing game for a chance to win a surprise box!🎁 👉 https://lnkd.in/ehZATchJ Attending CPHI Milan from October 8-10? You’re invited to scientifically analyse our capsule jar and submit your guess in person! Visit us at booth 5D139 in the Contract Manufacturing and Service Zone at CPHI. Schedule a meeting with us👉 https://lnkd.in/eV76T_Wq #CPHIMilan #CPHI2024 #ScienceCRO #NUVISAN

🚀 New publication alert! Some protein targets are notoriously difficult to crystallize. In such cases, rational surface modifications may help to promote crystal growth, in turn enabling the robust crystallization of challenging targets. Roman Hillig and colleagues from Structural Biology and Protein Sciences at Nuvisan have now published four such case studies with the protein kinases Aurora-C, IRAK4 & BUB1 and the KRAS-SOS1 complex. 👉 Read more here: https://lnkd.in/ezp3s43N To find out more on how we can help enable your drug discovery projects with Structural Biology support, visit https://lnkd.in/eKHKvKcE To check out our Xrays2Go portfolio: https://lnkd.in/e9MRV2cU or contact Simon Holton or Roman Hillig for more information. #StructuralBiology #ProteinScience #Xrays2Go #ScienceCRO #NUVISAN

📣 The 2nd NUVISAN Innovation Challenge is here! Do you have a groundbreaking idea and need support from venture capital firms and scientific experts? Submissions are now open for the 2nd NUVISAN Drug Discovery Innovation Challenge! 🎯This year, we're seeking innovative solutions for orphan diseases and challenging drug targets. Winners will get the chance to present their ideas to venture capitalists and receive expert scientific consultation from NUVISAN. 🌐 Companies from around the world addressing these unmet needs are encouraged to apply. 📅 The submission deadline is October 29. Explore the event details here: https://lnkd.in/e7skKGDP. We look forward to your application! #NUVISAN #ScienceCRO #InnovationChallenge #DrugDiscovery #OrphanDrugs

📯 Join Us for NUVISAN's Meet & Learn Event in Copenhagen! Following the success of last year's highly regarded NUVISAN Meet & Learn meetings in Germany and Austria, we’re bringing our experts to Copenhagen, Denmark, on October 29, 2024. At this event, our experts will share their insights into early drug discovery research, focusing on key principles, challenges, and innovative strategies that drive this critical phase of drug development. Featured presentations: ☑ Nuvisan Integrated Degrader Capabilities, presented by Duy Nguyen ☑ Brake the Driver: A Journey into KRAS Inhibition via SOS1, Fragment Screening, and HTS, presented by Benjamin Bader ☑ Targeting the Hippo Pathway in Cancer: Phenotypic Screening, Target, and Lead Optimization of Novel Small Molecule Inhibitors, presented by Peter Staller Beyond the presentations, this event offers valuable networking opportunities with industry peers from various organizations 🤝 Reserve your seat today -> https://lnkd.in/eSzubjZh #MeetandLearn #ScienceCRO #NUVISAN #DrugDiscovery #Screening #Protacs #Oncology